Sairy Hernandez

University of California, Los Angeles — United States

Medicine · Health Sciences

15h-index8.2kcitations55works4.22yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatocellular Carcinoma Treatment and Prognosis(41), Colorectal Cancer Treatments and Studies(21), Cancer, Lipids, and Metabolism(14), Cancer, Hypoxia, and Metabolism(12), Cholangiocarcinoma and Gallbladder Cancer Studies(6)

Publications55 total

EP.06.43 Using Artificial Intelligence to Leverage Phenotypic, Genomic and Proteomic Correlations in Lung Carcinoma Patients With MET Alterations

Journal of Thoracic Oncology·2025

Real-World Experiences Using Atezolizumab + Bevacizumab for the Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter Study

3 cited

Cancers·2025· 3 citedOpen Access

A Rare Presentation of Priapism From Pegylated Filgrastim During Treatment of Urothelial Cancer in an African-American Patient With Sickle Cell Trait

Cureus·2025Open Access

Atezolizumab Plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Real-World Experience From a US Community Oncology Network

4 cited

Journal of Hepatocellular Carcinoma·2025· 4 citedOpen Access

Real-world (RW) experience with atezolizumab + bevacizumab (A+B) for the treatment of unresectable HCC (uHCC): A multicenter study.

3 cited

Journal of Clinical Oncology·2025· 3 cited

Real-world Outcomes of Atezolizumab (A) Plus Bevacizumab (B) for Unresectable Hepatocellular Carcinoma: A Multicenter Study

HPB·2025

ASO Visual Abstract: Prognostic Significance of Recurrence and Timing of Recurrence on Survival Among Patients with Early-Stage Hepatocellular Carcinoma in US Clinical Practice

Annals of Surgical Oncology·2024

Prognostic Significance of Recurrence and Timing of Recurrence on Survival Among Patients with Early-Stage Hepatocellular Carcinoma in U.S. Clinical Practice

3 cited

Annals of Surgical Oncology·2024· 3 cited

Overall Survival in Real-World Patients with Unresectable Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab Versus Sorafenib or Lenvatinib as First-Line Therapy: Findings from the National Veterans Health Administration Database

1 cited

Cancers·2024· 1 citedOpen Access

P1.06A.05 Assessing Pathologic Response to Neoadjuvant Chemoimmunotherapy for NSCLC: Aligning Current Protocols with Artificial Intelligence

Journal of Thoracic Oncology·2024Open Access

Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab

25 cited

Journal of Clinical Oncology·2024· 25 citedOpen Access

Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave150

26 cited

Liver Cancer·2024· 26 citedOpen Access

Prognostic significance of real-world (RW) recurrence patterns after resection or ablation of early-stage hepatocellular carcinoma (HCC): Insights from the US Medicare population.

1 cited

Journal of Clinical Oncology·2024· 1 cited

Race/ethnicity and socioeconomic position in emergency department utilization in patients with hepatocellular carcinoma

3 cited

Future Oncology·2024· 3 citedOpen Access

Atezolizumab plus bevacizumab (A+B) in patients with unresectable hepatocellular carcinoma (uHCC): Real-world experience from a US community oncology network.

1 cited

Journal of Clinical Oncology·2024· 1 cited

Comparing first-line (1L) atezolizumab plus bevacizumab (A+B) to lenvatinib (L) or sorafenib (S) in patients with unresectable hepatocellular carcinoma (uHCC): Findings from the National Veteran Health Administration (VHA) database.

1 cited

Journal of Clinical Oncology·2024· 1 cited

Racial/ethnic disparities in the effectiveness of atezolizumab plus bevacizumab (A+B) vs. tyrosine kinase inhibitors (TKIs) among veterans with unresectable hepatocellular carcinoma (uHCC).

Journal of Clinical Oncology·2024

IMbrave050: Efficacy, safety and patient-reported outcomes (PROs) for adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in hepatocellular carcinoma (HCC) patients at high risk of disease recurrence after resection or ablation

2 cited

Journal of Hepatology·2023· 2 cited

Data from Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma

1 cited

2023· 1 citedOpen Access

Supplementary Table from Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma

2023Open Access

page 1 of 3Next →

Frequent Co-authors

Andrew X. Zhu(19), Zhenggang Ren(14), Yuxian Bai(14), Farshid Dayyani(13), Chia‐Jui Yen(13), Zhiqiang Meng(13), Hongming Pan(13), Paul Dillon(13), Shivani K. Mhatre(13), Vincent E. Gaillard(13), Robin Kate Kelley(13), Bruno Sangro(13), Masatoshi Kudo(11), Philippe Merle(10), Daneng Li(9), Wendy Verret(9), Ann‐Lii Cheng(9), Richard S. Finn(8), Peter R. Galle(7), Michel Ducreux(7)